

Applicants file an information disclosure statement concurrently herewith.

IN THE SPECIFICATION:

Please add the following section heading and paragraph directly after the title.

-- CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119(e) of United States Provisional Application No. 60/192,176, filed March 27, 2000; United States Provisional Application no. 60/192,179, filed March 27, 2000; United States Provisional Application No. 60/208,538, filed June 1, 2000; and United States Provisional Application No. 60/244,989, filed October 30, 2000.--

Please replace the four (4) consecutive paragraphs beginning on page 14, line 22 and ending on page 15, line 22, with the following four (4) consecutive replacement paragraphs:

-- Figure 1. Flow diagram for the generation of modified single-stranded oligonucleotides. The upper strands of chimeric oligonucleotides I and II are separated into pathways resulting in the generation of single-stranded oligonucleotides that contain (A) 2'-O-methyl RNA nucleotides or (B) phosphorothioate linkages. Fold changes in repair activity for correction of kan^r in the HUH7 cell-free extract are presented in parenthesis. HUH7 cells are described in Nakabayashi et al., Cancer Research 42: 3858-3863 (1982). Each single-stranded oligonucleotide is 25 bases in length and

$$\begin{array}{r} 2.04 \\ 1.15 \\ \hline 2.5 \end{array}$$
$$\begin{array}{r} 1.2 \\ 1.1 \\ \hline 2.3 \end{array}$$
$$\begin{array}{r} 1.1 \\ 1.0 \\ \hline 2.1 \end{array}$$

1.0925

**TARGETED CHROMOSOMAL GENOMIC ALTERATIONS
WITH MODIFIED SINGLE STRANDED OLIGONUCLEOTIDES**

This application claims benefit from United States Provisional Application No. 60/192,176, filed May 27, 2000; United States Provisional Application No. 60/192,179, filed May 27, 2000; United States Provisional Application No. 60/208,538, filed June 1, 2000; and United States Provisional Application No. 60/244,989, filed October 30, 2000.

Field Of The Invention

The technical field of the invention is oligonucleotide-directed repair or alteration of genetic information using novel chemically modified oligonucleotides. Such genetic information is preferably from a eukaryotic organism, i.e. a plant, animal or fungus.

Background Of The Invention

A number of methods have been developed specifically to alter the sequence of an isolated DNA in addition to methods to alter directly the genomic information of various plants, fungi and animals, including humans ("gene therapy"). The latter methods generally include the use of viral or plasmid vectors carrying nucleic acid sequences encoding partial or complete portions of a particular protein which is expressed in a cell or tissue to effect the alteration. The expression of the particular protein then results in the desired phenotype. For example, retroviral vectors containing a transgenic DNA sequence allowing for the production of a normal CFTR protein when administered to defective cells are described in U.S. Patent 5,240,846. Others have developed different "gene therapy vectors" which include, for example, portions of adenovirus (Ad) or adeno-associated virus (AAV), or other viruses. The virus portions used are often long terminal repeat sequences which are added to the ends of a transgene of choice along with other necessary control sequences which allow expression of the transgene. See U.S. Patents 5,700,470 and 5,139,941. Similar methods have been developed for use in plants. See, for example, U.S. Patent 4,459,355 which describes a method for transforming plants with a DNA vector and U.S. Patent 5,188,642 which describes cloning or expression vectors containing a transgenic DNA sequence which when expressed in plants confers resistance to the herbicide glyphosate. The use of such transgene vectors in any eukaryotic organism adds one or more exogenous copies of a gene, which

Insert
C9
before
B2 amendment
Cancel
1st paragraph

5

15

20

25